Positive association between Toll-like receptor 4 gene +896A/G polymorphism and susceptibility to gastric carcinogenesis: A meta-analysis

Tumor Biology

Volumn 34, Issue 4, 2013, Pages 2441-2450

  Zou, Tian Hui ^a   Wang, Zhen Hua ^a   Fang, Jing Yuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Gastric cancer; Meta analysis; Polymorphism; Precancerous gastric lesions; Toll like receptor 4

Indexed keywords

TOLL LIKE RECEPTOR 4;

ALLELE; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; GENETIC ASSOCIATION; HELICOBACTER INFECTION; HUMAN; PRECANCER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; STOMACH CANCER; SYSTEMATIC REVIEW; TOLL LIKE RECEPTOR 4 GENE;

EID: 84881482155     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0795-y     Document Type: Article

References (39)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer J Int Cancer. 2010;127(12):2893-917. doi: 10.1002/ijc.25516.
2. Valenti V, Hernandez-Lizoain JL, Beorlegui MC, Diaz-Gozalez JA, Regueira FM, Rodriguez JJ, et al. Morbidity, mortality, and pathological response in patients with gastric cancer preoperatively treated with chemotherapy or chemoradiotherapy. J Surg Oncol. 2011;104(2):124-9. doi: 10.1002/jso.21947.
3. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347(15):1175-86. doi: 10.1056/NEJMra020542.
4. Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988;48(13):3554-60.
5. Wong BC, Zhang L, Ma JL, Pan KF, Li JY, Shen L, et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut. 2012;61(6):812-8. doi: 10.1136/gutjnl-2011-300154.
6. Hishida A, Matsuo K, Goto Y, Hamajima N. Genetic predisposition to Helicobacter pylori-induced gastric precancerous conditions. World J Gastrointest Oncol. 2010;2(10):369-79. doi: 10.4251/wjgo.v2.i10.369.
7. El-Omar EM, Ng MT, Hold GL. Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene. 2008;27(2):244-52. doi: 10.1038/sj.onc.1210912.
8. Kutikhin AG. Impact of Toll-like receptor 4 polymorphisms on risk of cancer. Hum Immunol. 2011;72(2):193-206. doi: 10.1016/j.humimm.2010.11.003.
9. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000;25(2):187-91. doi: 10.1038/76048.
10. Jing JJ, Li M, Yuan Y. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in cancer: a meta-analysis. Gene. 2012;499(2):237-42. doi: 10.1016/j.gene.2012.03.045.
11. Zhang K, Zhou B, Wang Y, Rao L, Zhang L. The TLR4 gene polymorphisms and susceptibility to cancer: a systematic review and meta-analysis. Eur J Cancer. 2012. doi: 10.1016/j.ejca.2012.09.022.
12. Thakkinstian A, McElduff P, D'Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Med. 2005;24(9):1291-306. doi: 10.1002/sim.2010.
13. Xue H, Wang YC, Lin B, An J, Chen L, Chen J, et al. A meta-analysis of interleukin-10-592 promoter polymorphism associated with gastric cancer risk. PLoS One. 2012;7(7):e39868. doi: 10.1371/journal.pone.0039868.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557.
15. Xue P, Niu WQ, Jiang ZY, Zheng MH, Fei J. A meta-analysis of apolipoprotein E gene ε2/ε3/ε4 polymorphism for gallbladder stone disease. PLoS One. 2012;7(9):e45849. doi: 10.1371/journal.pone.0045849.
16. Niu W, Qi Y, Qian Y, Gao P, Zhu D. The relationship between apolipoprotein E ε2/ε3/ε4 polymorphisms and hypertension: a meta-analysis of six studies comprising 1812 cases and 1762 controls. Hypertens Res. 2009;32(12):1060-6. doi: 10.1038/hr.2009.164.
17. Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology. 2007;132(3):905-12. doi: 10.1053/j.gastro.2006.12.026.
18. Kato I, Canzian F, Plummer M, Franceschi S, van Doorn LJ, Vivas J, et al. Polymorphisms in genes related to bacterial lipopolysaccharide/peptidoglycan signaling and gastric precancerous lesions in a population at high risk for gastric cancer. Dig Dis Sci. 2007;52(1):254-61. doi: 10.1007/s10620-006-9303-1.
19. Achyut BR, Ghoshal UC, Moorchung N, Mittal B. Association of Toll-like receptor-4 (Asp299Gly and Thr399Ileu) gene polymorphisms with gastritis and precancerous lesions. Hum Immunol. 2007;68(11):901-7. doi: 10.1016/j.humimm. 2007.10.006.
20. Rigoli L, Di Bella C, Fedele F, Procopio V, Amorini M, Lo Giudice G, et al. TLR4 and NOD2/CARD15 genetic polymorphisms and their possible role in gastric carcinogenesis. Anticancer Res. 2010;30(2):513-7.
21. la Trejo-de OA, Torres J, Perez-Rodriguez M, Camorlinga-Ponce M, Luna LF, Abdo-Francis JM, et al. TLR4 single-nucleotide polymorphisms alter mucosal cytokine and chemokine patterns in Mexican patients with Helicobacter pylori-associated gastroduodenal diseases. Clin Immunol. 2008;129(2):333-40. doi: 10.1016/j.clim.2008.07.009.
22. Garza-Gonzalez E, Bosques-Padilla FJ, Mendoza-Ibarra SI, Flores-Gutierrez JP, Maldonado-Garza HJ, Perez-Perez GI. Assessment of the toll-like receptor 4 Asp299Gly, Thr399Ile and interleukin-8-251 polymorphisms in the risk for the development of distal gastric cancer. BMC Cancer. 2007;7:70. doi: 10.1186/1471-2407-7-70.
23. Santini D, Angeletti S, Ruzzo A, Dicuonzo G, Galluzzo S, Vincenzi B, et al. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol. 2008;154(3):360-4. doi: 10.1111/j.1365-2249.2008.03776.x.
24. de Oliveira JG, Rossi AF, Nizato DM, Miyasaki K, Silva AE. Profiles of gene polymorphisms in cytokines and Toll-like receptors with higher risk for gastric cancer. Dig Dis Sci. 2012. doi: 10.1007/s10620-012-2460-5.
25. Hommels MJ, Kroon AA, Netea MG, de Leeuw PW, Bruggeman CA, Leiner T, et al. The Asp299Gly Toll-like receptor 4 polymorphism in advanced aortic atherosclerosis. Neth J Med. 2007;65(6):203-7.
26. Li H, Sun B. Toll-like receptor 4 in atherosclerosis. J Cell Mol Med. 2007;11(1):88-95. doi: 10.1111/j.1582-4934.2007.00011.x.
27. Werner M, Topp R, Wimmer K, Richter K, Bischof W, Wjst M, et al. TLR4 gene variants modify endotoxin effects on asthma. J Allergy Clin Immunol. 2003;112(2):323-30.
28. Mockenhaupt FP, Cramer JP, Hamann L, Stegemann MS, Eckert J, Oh NR, et al. Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci U S A. 2006;103(1):177-82. doi: 10.1073/pnas.0506803102.
29. Schroder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis. 2005;5(3):156-64. doi: 10.1016/S1473-3099(05)01308-3.
30. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784-9. doi: 10.1056/NEJMoa001999.
31. Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012;104(6):488-92. doi: 10.1093/jnci/djs003.
32. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291(2):187-94. doi: 10.1001/jama.291.2. 187.
33. Tahara T, Arisawa T, Shibata T, Hirata I, Nakano H. Association of polymorphism of TLR4 and CD14 genes with gastroduodenal diseases in Japan. InflammoPharmacology. 2007;15(3):124-8.
34. Wu MS, Cheng TY, Shun CT, Lin MT, Chen LC, Lin JT. Functional polymorphisms of CD14 and Toll-like receptor 4 in Taiwanese Chinese with Helicobacter pylori-related gastric malignancies. Hepato-Gastroenterology. 2006;53(71):807-10.
35. Hishida A, Matsuo K, Goto Y, Mitsuda Y, Hiraki A, Naito M, et al. Toll-like receptor 4 +3725 G/C polymorphism, Helicobacter pylori seropositivity, and the risk of gastric atrophy and gastric cancer in Japanese. Helicobacter. 2009;14(1):47-53. doi: 10.1111/j.1523-5378.2009.00659.x.
36. Won HH, Kim JW, Kim MJ, Kim S, Park JH, Lee KA. Interleukin 10 polymorphisms differentially influence the risk of gastric cancer in East Asians and Caucasians. Cytokine. 2010;51(1):73-7. doi: 10.1016/j.cyto.2010.03.007.
37. Heidl G, Langhans P, Mellin W, Bunte H, Grundmann E. Adenocarcinomas of esophagus and cardia in comparison with gastric carcinoma. J Cancer Res Clin Oncol. 1993;120(1-2):95-9.
38. Kim MA, Lee HS, Yang HK, Kim WH. Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach. Cancer. 2005;103(7):1439-46. doi: 10.1002/cncr.20966.
39. Saito H, Fukumoto Y, Osaki T, Fukuda K, Tatebe S, Tsujitani S, et al. Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach. World J Surg. 2006;30(10):1864-9. doi: 10.1007/s00268-005-0582-z.